{
  "pmid": "41467564",
  "title": "Impact of ",
  "abstract": "Metformin-sulfonylurea combination is a widely prescribed as second-line therapy for type 2 diabetes mellitus (T2DM), yet patient responses vary due to individual genetic variation. These variations, particularly in AMP-activated protein kinase (AMPK) and its upstream regulator liver kinase B1 (LKB1), may contribute to differences in treatment response. This study investigated the association of  We enrolled 193 T2DM patients on metformin-sulfonylurea therapy after obtaining written consent. Glycemic and lipid parameters were assessed at baseline and after 3â€‰months. Genotyping was performed by PCR-RFLP and ARMS-PCR for  Genotype and allele distributions were not significantly different between responders and non-responders. Carriers of  We conclude that ",
  "disease": "diabetes mellitus"
}